Celgene Corporation (CELG) Shares Bought by Two Sigma Securities LLC

Two Sigma Securities LLC increased its stake in Celgene Corporation (NASDAQ:CELG) by 92.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,719 shares of the biopharmaceutical company’s stock after buying an additional 3,225 shares during the period. Two Sigma Securities LLC’s holdings in Celgene Corporation were worth $836,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Private Asset Management Inc. increased its position in Celgene Corporation by 3.2% in the first quarter. Private Asset Management Inc. now owns 1,832 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 57 shares during the last quarter. Capital Investment Services of America Inc. acquired a new position in Celgene Corporation during the first quarter valued at $203,000. Bridges Investment Management Inc. increased its position in Celgene Corporation by 2.8% in the first quarter. Bridges Investment Management Inc. now owns 134,645 shares of the biopharmaceutical company’s stock valued at $16,755,000 after buying an additional 3,622 shares during the last quarter. Chevy Chase Trust Holdings Inc. raised its position in Celgene Corporation by 3.2% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 720,403 shares of the biopharmaceutical company’s stock valued at $89,640,000 after buying an additional 22,612 shares during the last quarter. Finally, Burns J W & Co. Inc. NY raised its position in Celgene Corporation by 44.8% in the first quarter. Burns J W & Co. Inc. NY now owns 43,134 shares of the biopharmaceutical company’s stock valued at $5,367,000 after buying an additional 13,343 shares during the last quarter. 78.41% of the stock is currently owned by institutional investors and hedge funds.

Celgene Corporation (NASDAQ CELG) traded up 0.37% during midday trading on Friday, hitting $130.85. 1,019,500 shares of the stock traded hands. The stock has a market cap of $102.37 billion, a PE ratio of 40.52 and a beta of 1.89. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $139.00. The company has a 50-day moving average of $134.23 and a 200-day moving average of $124.17.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business’s revenue was up 18.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.44 earnings per share. On average, equities research analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Celgene Corporation (CELG) Shares Bought by Two Sigma Securities LLC” was originally reported by Stock Observer and is owned by of Stock Observer. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.thestockobserver.com/2017/08/12/celgene-corporation-celg-shares-bought-by-two-sigma-securities-llc.html.

CELG has been the subject of several research reports. Jefferies Group LLC set a $154.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Saturday, May 13th. Vetr lowered shares of Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $132.90 price target for the company. in a research report on Thursday, May 11th. BTIG Research restated a “buy” rating and set a $138.00 price target on shares of Celgene Corporation in a research report on Monday, May 1st. Cantor Fitzgerald set a $159.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, April 27th. Finally, Cann restated a “buy” rating on shares of Celgene Corporation in a research report on Thursday, April 27th. One analyst has rated the stock with a sell rating, six have given a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $147.00.

In other news, insider Robert J. Hugin sold 175,970 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total value of $23,604,615.80. Following the completion of the sale, the insider now directly owns 1,033,909 shares in the company, valued at $138,688,553.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gilla Kaplan sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total value of $1,008,900.00. Following the completion of the sale, the director now owns 76,301 shares of the company’s stock, valued at $10,264,010.52. The disclosure for this sale can be found here. Insiders sold 235,255 shares of company stock valued at $31,377,042 over the last 90 days. Company insiders own 0.95% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply